...
首页> 外文期刊>Coordination chemistry reviews >Recent advances in metallodrug-like molecules targeting non-coding RNAs in cancer chemotherapy
【24h】

Recent advances in metallodrug-like molecules targeting non-coding RNAs in cancer chemotherapy

机译:靶向非编码RNA的金属药物样分子在癌症化疗中的最新进展

获取原文
获取原文并翻译 | 示例
           

摘要

New drug discovery strategies are emerging at a rapid pace to combat the threat of mortality caused by various chronic diseases viz., HIV-AIDS, respiratory infections and cancers. The therapeutic intervention is necessary for synthesizing robust pharmaceuticals and to unlock the mechanistic aspects of pathogens involved in diseases. These therapeutic regimes have diverted from traditional target DNA to new exciting novel targets viz., structured proteins, enzyme receptors, ribonucleoprotein (RNP) particles and non coding RNAs. RNA has much attractive prospectus as an antitumor therapeutic target being involved in many essential biochemical, genetic and epigenetic functions of the cell. The structural flexibility of RNA both in secondary and tertiary structure owing to which selective binding based on structures rather than sequence is possible while RNP particles have exhibited reasonable therapeutic success in the antibacterial area. RNA was much ignored and underexploited target due to difficulty in characterisation and unavailability of sensitive biophysical/biochemical techniques to study its intricate threedimensional folds. However, recent developments have provided valuable insights into RNA targets, and its binding abilities, the small molecule RNA-based drugs have emerged, and many antitumor lead compounds targeted to RNA including organic dyes, intercalative cations, aminoglycoside antibiotics and inorganic metal complexes were isolated, and some of them have reached clinical trial phases in drug discovery. Interestingly, the development of high-resolution RNA structural analysis, using both X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy has clearly made a profound impact in this area. In the present review, we are looking at more naive options of modulating drug discovery strategies involving metallodrugs derived from transition metal ions which are targeted to ncRNAs. Metal complexes exhibit diversity in size and structure beyond the geometries of carbon, possess photo physical and electrochemical properties and therefore are considered as an important class of structure selective binding agents for nucleic acids. Herein, we describe innovative rational designs of metallodrugs targeted to non-coding RNA structures and their future biological prospectus in drug design. (C) 2019 Elsevier B.V. All rights reserved.
机译:新的药物发现策略正在迅速发展,以应对各种慢性疾病(如艾滋病毒/艾滋病,呼吸道感染和癌症)造成的死亡威胁。治疗干预对于合成强大的药物和释放与疾病有关的病原体的机制方面是必需的。这些治疗方案已经从传统的靶DNA转移到了新的令人兴奋的新型靶,即结构蛋白,酶受体,核糖核蛋白(RNP)颗粒和非编码RNA。 RNA具有非常诱人的招募说明书作为抗肿瘤治疗靶标,涉及细胞的许多基本生化,遗传和表观遗传功能。由于RNP颗粒在抗菌领域显示出合理的治疗成功,由于RNA可能具有基于结构而不是序列的选择性结合,因此具有二级和三级结构的RNA结构灵活性。由于难以表征和无法利用灵敏的生物物理/生化技术研究其复杂的三维折叠,因此RNA被忽略并被未充分利用。但是,最近的发展为RNA靶标及其结合能力提供了有价值的见解,基于RNA的小分子药物应运而生,并且分离了许多针对RNA的抗肿瘤先导化合物,包括有机染料,嵌入阳离子,氨基糖苷类抗生素和无机金属络合物。 ,其中一些已进入药物发现的临床试验阶段。有趣的是,同时使用X射线晶体学和核磁共振(NMR)光谱技术进行高分辨率RNA结构分析的发展显然已对该领域产生了深远的影响。在当前的审查中,我们正在寻找调节涉及到ncRNAs的过渡金属离子衍生的金属药物的药物发现策略的更多天真选择。金属络合物在尺寸和结构上都超过碳的几何形状,表现出多样性,具有光物理和电化学性质,因此被认为是核酸的一类重要的结构选择性结合剂。在本文中,我们描述了针对非编码RNA结构的金属药物的创新合理设计及其在药物设计中的未来生物学说明书。 (C)2019 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号